Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
NCT00886769 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2017-03-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “recommendation by Data Monitoring Committee” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-02-27Phase 3 first posted: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT03447769)
- 2017-08-22Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (ACZ885) + Placebo (NCT01731990)
- 2017-07-13Results posted on the registry: AbbVie, ABT-981 + Placebo for ABT-981 (NCT02384538)
- 2017-07-02Also stopped (withdrawn): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), XOMA 052 (NCT01211977)
- 2017-06-08Results posted on the registry: Novartis Pharmaceuticals, Canakinumab, ACZ885 + Triamcinolone acetonide (NCT01362608)
- 2017-06-08Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab, ACZ885 + Triamcinolone acetonide (NCT01362608)
- 2017-04-20Also stopped (withdrawn): Novartis Pharmaceuticals, ACZ885 + Triamcinelone acetonide (NCT01593527)
- 2017-03-17Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT02059291)
- 2017-03-10Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT00891046)
- 2017-02-17Also stopped (withdrawn): Novartis Pharmaceuticals, Canakinumab (NCT02980263)
- 2017-02-14Also stopped (terminated): University Hospital, Basel, Switzerland, Canakinumab + Placebo (NCT01805960)
- 2016-11-21Results posted on the registry: Novartis Pharmaceuticals, ACZ885 + Placebo (NCT02007252)
- 2016-10-18Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), canakinumab (anti IL-1beta) + Placebo (NCT00947427)
- 2016-09-22Phase 3 first posted: Novartis Pharmaceuticals, Canakinumab (AIN457) (NCT02911857)
- 2016-08-03Results posted on the registry: Novartis Pharmaceuticals, ACZ885 (NCT01576367)
- 2016-07-12Also stopped (terminated): XOMA (US) LLC, Placebo + Dose 1 gevokizumab (NCT01747538)
- 2016-04-27Also stopped (terminated): XOMA (US) LLC, gevokizumab + Placebo (NCT02326740)
- 2016-04-27Also stopped (terminated): XOMA (US) LLC, gevokizumab + Placebo (NCT02315417)
- 2016-04-27Also stopped (terminated): XOMA (US) LLC, gevokizumab (NCT02318914)
- 2016-04-08Also stopped (terminated): XOMA (US) LLC, Placebo + Dose 1 gevokizumab (NCT01684345)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision